These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study. Ville S; Imbert-Marcille BM; Coste-Burel M; Garandeau C; Meurette A; Cantarovitch D; Giral M; Hourmant M; Blancho G; Dantal J Transpl Int; 2018 May; 31(5):484-494. PubMed ID: 29057508 [TBL] [Abstract][Full Text] [Related]
37. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease]. Hao QF; Sheng GY; Luan Z Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931 [TBL] [Abstract][Full Text] [Related]
38. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Comoli P; Maccario R; Locatelli F; Valente U; Basso S; Garaventa A; Tomà P; Botti G; Melioli G; Baldanti F; Nocera A; Perfumo F; Ginevri F Am J Transplant; 2005 Jun; 5(6):1415-22. PubMed ID: 15888049 [TBL] [Abstract][Full Text] [Related]
39. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Dharnidharka VR; Douglas VK; Hunger SP; Fennell RS Pediatr Transplant; 2004 Feb; 8(1):87-90. PubMed ID: 15009846 [TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus infection in children with renal transplantation: A single-centre experience. You J; Kim M; Lee J; Han DJ; Park YS; Lee JH Nephrology (Carlton); 2018 Nov; 23(11):1039-1045. PubMed ID: 28869325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]